NCT05285137 is a Phase 1 clinical trial of CD388 Injection in Healthy, sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Who is sponsoring NCT05285137?

NCT05285137 is sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT05285137?

Interventions in NCT05285137: CD388 Injection, Saline placebo.

Is NCT05285137 still recruiting?

NCT05285137 is currently completed. Last updated 27 February 2025.

Are results published for NCT05285137?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-27 · How we verify

NCT05285137

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Completed Phase 1 Results posted Last updated 27 February 2025

What this trial tests

Phase 1 trial testing CD388 Injection in Healthy in 77 participants. Completed in 27 October 2023.

Timeline

14 March 2022

Primary endpoint
27 October 2023

27 October 2023

Quick facts

Lead sponsor	Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	prevention
Enrollment	77
Start date	14 March 2022
Primary completion	27 October 2023
Estimated completion	27 October 2023
Sites	1 location across United States

Drugs / interventions tested

CD388 Injection
Saline placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 Primary · Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Participants with at least one TEAE

Group	Value	95% CI
CD388 50 mg IM	5
CD388 150 mg IM	5
CD388 450 mg IM	5
Pooled Placebo IM	8
CD388 50 mg SQ	5
CD388 150 mg SQ	4
CD388 450 mg SQ	5
CD388 900 mg SQ	3
Pooled Placebo SQ	7

Participants with AEs leading to study withdrawal

Group	Value	95% CI
CD388 50 mg IM	0
CD388 150 mg IM	0
CD388 450 mg IM	0
Pooled Placebo IM	0
CD388 50 mg SQ	0
CD388 150 mg SQ	0
CD388 450 mg SQ	2
CD388 900 mg SQ	0
Pooled Placebo SQ	0

Severity of TEAEs After a Single Dose of CD388 Primary · Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Mild

Group	Value	95% CI
CD388 50 mg IM	5
CD388 150 mg IM	5
CD388 450 mg IM	2
Pooled Placebo IM	5
CD388 50 mg SQ	4
CD388 150 mg SQ	4
CD388 450 mg SQ	3
CD388 900 mg SQ	3
Pooled Placebo SQ	6

Moderate

Group	Value	95% CI
CD388 50 mg IM	0
CD388 150 mg IM	0
CD388 450 mg IM	3
Pooled Placebo IM	2
CD388 50 mg SQ	1
CD388 150 mg SQ	0
CD388 450 mg SQ	1
CD388 900 mg SQ	0
Pooled Placebo SQ	1

Severe

Group	Value	95% CI
CD388 50 mg IM	0
CD388 150 mg IM	0
CD388 450 mg IM	0
Pooled Placebo IM	1
CD388 50 mg SQ	0
CD388 150 mg SQ	0
CD388 450 mg SQ	1
CD388 900 mg SQ	0
Pooled Placebo SQ	0

Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	4.13	± 0.747
Cohort 2A CD388 150 mg IM	10.4	± 2.44
Cohort 3A CD388 450 mg IM	48.6	± 11.7
Cohort 1B CD388 50 mg SQ	3.57	± 0.942
Cohort 2B CD388 150 mg SQ	12.0	± 3.35
Cohort 3B CD388 450 mg SQ	32.7	± 9.40
Cohort 4B CD388 900 mg SQ	58.8	± 17.5

Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	3.96	2.91 – 5.34
Cohort 2A CD388 150 mg IM	10.4	6.52 – 13.6
Cohort 3A CD388 450 mg IM	48.0	35.2 – 67.7
Cohort 1B CD388 50 mg SQ	3.72	2.17 – 4.83
Cohort 2B CD388 150 mg SQ	11.8	6.84 – 17.0
Cohort 3B CD388 450 mg SQ	31.6	16.6 – 48.0
Cohort 4B CD388 900 mg SQ	60.7	34.3 – 91.3

Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	111.08	± 72.42
Cohort 2A CD388 150 mg IM	159.03	± 83.10
Cohort 3A CD388 450 mg IM	85.64	± 42.19
Cohort 1B CD388 50 mg SQ	213.00	± 108.43
Cohort 2B CD388 150 mg SQ	137.48	± 77.82
Cohort 3B CD388 450 mg SQ	120.04	± 67.83
Cohort 4B CD388 900 mg SQ	109.54	± 55.66

Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	96.07	48.17 – 240.00
Cohort 2A CD388 150 mg IM	131.98	71.97 – 312.00
Cohort 3A CD388 450 mg IM	78.31	24.17 – 144.00
Cohort 1B CD388 50 mg SQ	228.00	72.00 – 312.02
Cohort 2B CD388 150 mg SQ	131.28	48.22 – 312.02
Cohort 3B CD388 450 mg SQ	96.00	48.17 – 240.00
Cohort 4B CD388 900 mg SQ	96.00	48.17 – 192.00

Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	1234.41	± 140.04
Cohort 2A CD388 150 mg IM	1192.03	± 235.80
Cohort 3A CD388 450 mg IM	1006.20	± 314.39
Cohort 1B CD388 50 mg SQ	1069.78	± 216.48
Cohort 2B CD388 150 mg SQ	1265.53	± 223.93
Cohort 3B CD388 450 mg SQ	1065.21	± 239.19
Cohort 4B CD388 900 mg SQ	1384.36	± 282.53

MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	1275.62	985.09 – 1390.45
Cohort 2A CD388 150 mg IM	1285.85	783.24 – 1471.71
Cohort 3A CD388 450 mg IM	1137.42	540.88 – 1384.09
Cohort 1B CD388 50 mg SQ	1052.39	685.81 – 1350.50
Cohort 2B CD388 150 mg SQ	1270.40	796.65 – 1576.21
Cohort 3B CD388 450 mg SQ	1040.30	809.64 – 1502.38
Cohort 4B CD388 900 mg SQ	1287.45	1110.87 – 1998.04

Mean Apparent Clearance (CL/F) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	0.00751	± 0.00119
Cohort 2A CD388 150 mg IM	0.00867	± 0.00177
Cohort 3A CD388 450 mg IM	0.00766	± 0.00199
Cohort 1B CD388 50 mg SQ	0.00900	± 0.00230
Cohort 2B CD388 150 mg SQ	0.00725	± 0.00123
Cohort 3B CD388 450 mg SQ	0.00883	± 0.00213
Cohort 4B CD388 900 mg SQ	0.00863	± 0.00158

Median Apparent Clearance (CL/F) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	0.00707	0.00614 – 0.00991
Cohort 2A CD388 150 mg IM	0.00851	0.00640 – 0.0112
Cohort 3A CD388 450 mg IM	0.00726	0.00571 – 0.0116
Cohort 1B CD388 50 mg SQ	0.00834	0.00591 – 0.0128
Cohort 2B CD388 150 mg SQ	0.00717	0.00551 – 0.00909
Cohort 3B CD388 450 mg SQ	0.00912	0.00493 – 0.0115
Cohort 4B CD388 900 mg SQ	0.00870	0.00648 – 0.0111

Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	13.3	± 1.91
Cohort 2A CD388 150 mg IM	14.8	± 4.40
Cohort 3A CD388 450 mg IM	10.7	± 2.99
Cohort 1B CD388 50 mg SQ	13.4	± 2.59
Cohort 2B CD388 150 mg SQ	13.3	± 3.70
Cohort 3B CD388 450 mg SQ	13.1	± 2.61
Cohort 4B CD388 900 mg SQ	17.1	± 3.76

Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388 Secondary · Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Group	Value	95% CI
Cohort 1A CD388 50 mg IM	13.9	10.3 – 15.8
Cohort 2A CD388 150 mg IM	14.4	11.1 – 23.9
Cohort 3A CD388 450 mg IM	10.9	6.47 – 15.1
Cohort 1B CD388 50 mg SQ	12.2	11.4 – 18.7
Cohort 2B CD388 150 mg SQ	12.7	9.27 – 20.7
Cohort 3B CD388 450 mg SQ	12.9	10.7 – 18.9
Cohort 4B CD388 900 mg SQ	16.7	11.2 – 24.2

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected for all participants from the time of signing the informed consent form through the final study visit (Day 120 for the 50 mg dose arm [Cohorts 1A/1B]; Day 412 for the 150 mg and 450 mg dose arms [Cohorts 2A/2B and 3A/3B]; and Day 206 for the 900 mg dose arm [Cohort 4B]).. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

CD388 50 mg IM

Serious: 0/8 (0%)

Deaths: 0/8

CD388 150 mg IM

Serious: 0/8 (0%)

Deaths: 0/8

CD388 450 mg IM

Serious: 0/8 (0%)

Deaths: 0/8

Pooled Placebo IM

Serious: 0/9 (0%)

Deaths: 0/9

CD388 50 mg SQ

Serious: 0/8 (0%)

Deaths: 0/8

CD388 150 mg SQ

Serious: 0/8 (0%)

Deaths: 0/8

CD388 450 mg SQ

Serious: 0/8 (0%)

Deaths: 0/8

CD388 900 mg SQ

Serious: 0/8 (0%)

Deaths: 0/8

Pooled Placebo SQ

Serious: 0/12 (0%)

Deaths: 0/12

Other adverse events (65 terms — click to expand)

Reaction	System	CD388 50 mg IM	CD388 150 mg IM	CD388 450 mg IM	Pooled Placebo IM	CD388 50 mg SQ	CD388 150 mg SQ	CD388 450 mg SQ	CD388 900 mg SQ	Pooled Placebo SQ
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—
Viral infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Presyncope	Nervous system disorders	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Somnolence	Nervous system disorders	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Saliva discoloration	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Diarrhea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—
Feces hard	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Dermatitis contact	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Acne	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Arthropod bite	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Pustule	Infections and infestations	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Cerumen impaction	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Sunburn	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Streptococcal infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Injection site hemorrhage	General disorders	—	—	—	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Blepharitis	Eye disorders	—	—	—	—	—	—	—	—	—
Edema peripheral	General disorders	—	—	—	—	—	—	—	—	—
Proctalgia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Vessel puncture site hematoma	General disorders	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—	—	—
Blood pressure systolic increased	Investigations	—	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT05285137 adverse events section.

Sponsor's own description

The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.
Bonomini A, Mercorelli B, Loregian A. · · 2025 · cited 24× · PMID 39945883 · DOI 10.1007/s00018-025-05611-1
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.
Döhrmann S, Levin J, Cole JN, Borchardt A, et al · · 2025 · cited 8× · PMID 40097766 · DOI 10.1038/s41564-025-01955-3
Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study.
Rojas RE, Equils O, Villacian J, Mann A, et al · · 2025 · PMID 41060047 · DOI 10.1093/cid/ciaf465
CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase
Döhrmann S, Levin J, Cole JN, Borchardt A, et al · · 2024 · DOI 10.1101/2024.06.04.597465
2116. Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI)
· 2023

Verify or expand the search:

Other trials of CD388 Injection

Trials testing the same drug.

NCT06609460 — Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications · Phase 2 · completed
NCT05619536 — Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT06609460 — Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications · Phase 2 · completed
NCT05619536 — Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects · Phase 1 · completed
NCT05523089 — The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults · Phase 2 · completed
NCT03667690 — Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis · Phase 3 · completed
NCT02888197 — Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05285137 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05285137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT05285137

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of CD388 Injection

Other recruiting trials for Healthy

Other Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Verify against primary sources